Hims & Hers Health, Inc. (HIMS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 17/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 25.97% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?
- Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch
- What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean?
- Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
- HIMS Stock Snaps 3-Day Slump On Peptide Hopes: Trump Administration Reviews Plan That Could Unlock $2.2B Market
- Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
- Should You Trim Or Add To Your Hims & Hers Position Now?
- Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Hims & Hers Health, Inc..
Full HIMS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.